Skip to main content
SBFM logo

SBFM

Sunshine Biopharma Inc.
$2.11 -0.07 (-3.21%) At close · Jul 2
Market Cap
$10.56M
Shares
5,005,945

Price & Indicators

20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$2.11 Open$2.15 Day$2.10–2.20 52W$0.25–3.05 Avg vol 30d11.8M Short int175K · 3.5% float · 1.0d Short vol40% Last earningsApr 9, 2026 DataFeb 2022–Jul 2026 Filing10-Q · May 13
Equibles Rating blended score · not investment advice
Overall
Buy
Technical · trend & momentum Buy
+ 50 / 200-day cross golden cross
+ Price vs 200-day avg +53% above
+ Price vs 50-day avg +46% above
RSI (14) 58 · neutral
MACD trend negative
52-week position 66% · mid-range
Sentiment · smart money Bullish
+ Trend (MA cross) 50d $1 › 200d $1 — 50d above 200d
Institutional flow -8% holders QoQ · +3 funds added
Insider flow No net insider activity over 90 days
+ Short interest 3.49% of float · ▼ -87.9% MoM · 1.0 days cover
Volume signal Volume near normal
Institution breadth 12 holders — mid 1-yr range
Fundamentals Strong
Revenue growth +4% Y/Y
+ Gross margin 34%, expanding
+ EPS growth +98% Y/Y
Free cash flow $-5.5M
+ Buyback $2.0M authorized
+ Balance sheet net cash $20.9M

Blended from price, positioning & fundamentals · daily-close · not investment advice.

Up next
Next earnings call
Aug 30, 2026 Est · unconfirmed · in 8 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
filed May 13, 2026

Technicals

trend & momentum for long-term holders Buy
1 · 2 · 3
50 / 200-day cross
golden cross Bullish
Price vs 200-day avg
+53% above Bullish
Price vs 50-day avg
+46% above Bullish
RSI (14)
58 · neutral Neutral
MACD trend
negative Bearish
52-week position
66% · mid-range Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) Golden cross
50d $1 › 200d $1 — 50d above 200d
Institutional flow Distributing
-8% holders QoQ · +3 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
3.49% of float · ▼ -87.9% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
12 holders — mid 1-yr range
Price context
position in its 52-week range
52-wk low $0 Now $2 · 66% 52-wk high $3
vs 200-day avg +53% vs 50-day avg +46% 50-day above 200-day golden cross

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Drug Manufacturers - Specialty & Generic — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
SBFM
Sunshine Biopharma Inc.
this stock
$10.56M +71.5% +4.1% 3.5%
TAK
Takeda Pharmaceutical Co Ltd
$52.99B +7.6% 0.3%
GALDY
Galderma Group AG/ADR
$52.48B +8.0% 0.0%
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR
$45.13B 0.0%
HLN
Haleon plc
$43.25B -2.9% 0.2%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
12
% held
2.4%
Net QoQ
+7.2K sh
Top holder
CITADEL ADVISORS LLC
Held Float
View
Short & Settlement
Short Interest Falling
Shares short
174.7K
Days to cover
1.0d
Change
-1.3M sh
View
Short Volume
Short vol %
40%
As of
Jul 2, 2026
Short Total
View
Fails to Deliver
FTD shares
10.2K
Value
$24.1K
As of
Jun 12, 2026
View
Off-Exchange
Off-exchange %
81.8%
Week of
May 4, 2026
Off-exch Lit
View
Smart Money
Congressional Trades Buy
Member
Roger Williams
Amount
$1.0K–$15.0K
Traded
Jun 30, 2022
View
Financials
Financials
Revenue (FY)
$36.3M
Net income (FY)
$-6.0M
EPS diluted
$-7.32
View
Buybacks
Authorized
$2.0M
View
Filings
SEC Filings
Latest
8-K
Filed
May 29, 2026
This year
8
View
Exempt Offerings
Offering
$5.0M
Filed
May 17, 2023
View
Earnings & Events
Earnings Calls
Last call
Apr 9, 2026
View

Performance

5D 20D 120D MTD YTD
SBFM -1.4% -20.7% +54.0% +0.5% +71.5%
SPY +1.4% -1.3% +8.0% -0.3% +9.2%
vs SPY -2.8% -19.4% +46.0% +0.8% +62.3%

Capital returns

Buyback program · as of Jan 19, 2023
Authorized
$2.00M
Spent (derived)
Remaining

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 1402328 CUSIP 867781700 Visit website Investor relations